Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications

Cancer Research
Tatiana PopovaMarc-Henri Stern

Abstract

CDK12 is a recurrently mutated gene in serous ovarian carcinoma, whose downregulation is associated with impaired expression of DNA damage repair genes and subsequent hypersensitivity to DNA-damaging agents and PARP1/2 inhibitors. In this study, we investigated the genomic landscape associated with CDK12 inactivation in patients with serous ovarian carcinoma. We show that CDK12 loss was consistently associated with a particular genomic instability pattern characterized by hundreds of tandem duplications of up to 10 megabases (Mb) in size. Tandem duplications were characterized by a bimodal (∼0.3 and ∼3 Mb) size distribution and overlapping microhomology at the breakpoints. This genomic instability, denoted as the CDK12 TD-plus phenotype, is remarkably distinct from other alteration patterns described in breast and ovarian cancers. The CDK12 TD-plus phenotype was associated with a greater than 10% gain in genomic content and occurred at a 3% to 4% rate in The Cancer Genome Atlas-derived and in-house cohorts of patients with serous ovarian carcinoma. Moreover, CDK12-inactivating mutations together with the TD-plus phenotype were also observed in prostate cancers. Our finding provides new insight toward deciphering the function of...Continue Reading

References

Apr 17, 2008·Cell Cycle·Bertrand LlorenteLorraine S Symington
Aug 30, 2008·Nature Reviews. Cancer·J Julian Blow, Peter J Gillespie
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Jun 23, 2009·Genome Research·Martin KrzywinskiMarco A Marra
Nov 13, 2009·PloS One·Nils HomerStanley F Nelson
Dec 25, 2009·Nature·Philip J StephensMichael R Stratton
Jan 30, 2010·Bioinformatics·Aaron R Quinlan, Ira M Hall
Jul 6, 2010·Nucleic Acids Research·Kai WangHakon Hakonarson
Jan 12, 2011·Nature Biotechnology·James T RobinsonJill P Mesirov
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Dec 21, 2011·The Journal of Pathology·Charlotte K Y NgJames D Brenton
Apr 20, 2012·The Journal of Pathology·David J McBrideDavid Dl Bowtell
May 12, 2012·Cancer Discovery·Nicolai J BirkbakAndrea L Richardson
Feb 8, 2014·Trends in Genetics : TIG·Diego OttavianiDenise Sheer
Mar 13, 2014·DNA Repair·Nicholas R PannunzioMichael R Lieber
Apr 22, 2015·International Journal of Cancer. Journal International Du Cancer·Oumou GoundiamXavier Sastre-Garau
May 23, 2015·Cell·Dan RobinsonArul M Chinnaiyan
Jul 21, 2015·Biochimica Et Biophysica Acta·Bartlomiej BartkowiakArno L Greenleaf

❮ Previous
Next ❯

Citations

Aug 21, 2016·Proceedings of the National Academy of Sciences of the United States of America·Johnathan WatkinsAnita Grigoriadis
Aug 21, 2016·Proceedings of the National Academy of Sciences of the United States of America·Francesca Menghi, Edison T Liu
Sep 24, 2016·Cancer Treatment Reviews·Rosaria ChilàGiovanna Damia
Jul 4, 2017·International Journal of Cancer. Journal International Du Cancer·Sabrina SchecherKatrin E Tagscherer
Oct 14, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hana PaculováJiří Kohoutek
Nov 24, 2017·Nature·Nicholas A WillisRalph Scully
Oct 4, 2018·BJU International·Evan W WarnerAlexander W Wyatt
May 1, 2019·Cellular and Molecular Life Sciences : CMLS·Rakesh SrivastavaSeong Hoon Ahn
Aug 15, 2018·Journal of Clinical Pathology·Goldie Y L LuiChristopher J Kemp
Sep 11, 2019·Advances in Anatomic Pathology·Farzana A Faisal, Tamara L Lotan
Mar 17, 2020·Familial Cancer·Alexandre EeckhoutteMarc-Henri Stern
Jul 1, 2016·Oncotarget·Cefan ZhouJingfeng Tang
May 27, 2020·Experimental & Molecular Medicine·Seung Hyuk ChoiKatherine A Jones
Nov 2, 2017·Cell Division·Hana Paculová, Jiří Kohoutek
Aug 15, 2018·Nature Genetics·Geoff MacintyreJames D Brenton
Oct 26, 2018·British Journal of Cancer·Darren R HodgsonJ Carl Barrett
Jun 21, 2019·JCO Precision Oncology·Jon H ChungNeeraj Agarwal
Jul 2, 2019·Frontiers in Oncology·Natalia V BogdanovaThilo Dörk
Oct 28, 2019·Biomolecules·Bartlomiej BartkowiakArno L Greenleaf
Mar 24, 2017·Nucleic Acids Research·Jerry F TienGregg B Morin
Jul 28, 2019·EMBO Reports·Anil Paul Chirackal ManavalanDalibor Blazek
Feb 7, 2020·Nature·Yilong LiUNKNOWN PCAWG Consortium
Dec 10, 2020·Future Medicinal Chemistry·Solomon TadesseAndrii Monastyrskyi
Oct 30, 2020·Molecular Cancer Research : MCR·Wennuan LiuJianfeng Xu
Oct 30, 2020·Cancer Management and Research·Ioannis A Voutsadakis
Jan 22, 2021·Current Opinion in Genetics & Development·Jeremy SettonSimon N Powell
Jan 9, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan WarnerAlexander W Wyatt
Apr 10, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AnnalaK N Chi
Jul 29, 2021·Nature Reviews. Cancer·Gene KohSerena Nik-Zainal
Sep 18, 2021·Bioinformatics·Itsuki SugitaShumpei Ishikawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.